Most Frequent Side Effects from Keytruda Treatment
Keytruda (pembrolizumab), an immunotherapy for cancers like melanoma and lung cancer, commonly causes fatigue (up to 45% of patients), musculoskeletal pain (30-35%), decreased appetite (25-30%), nausea (20-25%), diarrhea (20%), rash (15-20%), cough (15-20%), itching (15%), constipation (15%), and fever (10-15%). These occur across approved uses and increase with combination therapies like chemotherapy.[1][2]
Side Effects by Body System
- Skin issues: Rash, itching, vitiligo (skin depigmentation).
- Digestive: Nausea, diarrhea, constipation, abdominal pain.
- Respiratory: Cough, shortness of breath.
- Musculoskeletal: Pain in joints, muscles, back.
- General: Fatigue, fever, weight loss, headache.[1][3]
Severe or Immune-Related Side Effects
Keytruda boosts immune attacks on cancer but can trigger inflammation in healthy tissues (immune-related adverse events, or irAEs):
- Endocrine: Thyroid problems (hypo- or hyperthyroidism, 15-20%), adrenal insufficiency.
- Lung: Pneumonitis (3-5%, potentially fatal).
- Gastrointestinal: Colitis (1-2%).
- Liver: Hepatitis.
- Other: Infusion reactions, myocarditis, encephalitis (rare but serious, <1%). About 10-15% of patients need steroids or hospitalization; hold or stop Keytruda if severe.[1][2][4]
Side Effects in Combination Therapies
With chemo (e.g., Keytruda + pemetrexed/platinum for NSCLC), rates rise: anemia (40%), nausea (55%), fatigue (50%). With axitinib for kidney cancer, hypertension (50%) and diarrhea (40%) dominate.[1][3]
Differences Across Cancer Types
Non-small cell lung cancer patients report higher fatigue and rash; melanoma sees more vitiligo and colitis. Head/neck cancer combos amplify mouth sores and hypothyroidism.[1][2]
What Patients Experience Long-Term
Many side effects start within weeks but some persist post-treatment, like ongoing thyroid issues (up to 20% permanent). Regular monitoring with blood tests and scans catches irAEs early.[4]
Managing Side Effects
Doctors grade severity (1 mild to 4 life-threatening). Mild ones need supportive care; severe require immunosuppressants. Report new symptoms immediately—don't wait for infusions.[1][3]
[1]: Keytruda Prescribing Information, Merck (FDA-approved label, latest Dec 2023). https://www.keytruda.com/
[2]: NCCN Guidelines for Immunotherapy Toxicity (v2.2024). https://www.nccn.org/
[3]: ClinicalTrials.gov summaries (e.g., KEYNOTE-024, -189 trials). https://clinicaltrials.gov/
[4]: ASCO Guidelines on Immune-Related Adverse Events (2021). https://ascopubs.org/doi/10.1200/JCO.21.01440